NCT06947135 Stellate Ganglion Morphine Infiltration on Myocardial Ischemia-Reperfusion Injury
| NCT ID | NCT06947135 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The Second Hospital of Anhui Medical University |
| Condition | Acute Myocardial Infarction |
| Study Type | INTERVENTIONAL |
| Enrollment | 166 participants |
| Start Date | 2025-05-29 |
| Primary Completion | 2026-06-04 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 166 participants in total. It began in 2025-05-29 with a primary completion date of 2026-06-04.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to investigate whether morphine modulates the functions of the stellate ganglion to reduce myocardial ischemia/reperfusion injury in AMI patients. It will also assess the safety of injecting morphine around the stellate ganglion via ultrasound guidance. The main questions it aims to answer are: 1. Does morphine regulate stellate ganglion function to reduce myocardial ischemia/reperfusion injury in AMI patients? 2. What medical problems do participants experience when receiving injected morphine around the stellate ganglion? Researchers will compare morphine to a placebo saline (as a control group) to determine whether stellate ganglion infiltration with morphine effectively treats patients with AMI following primary PCI. Participants will: * Receive a single injection of morphine or saline around the stellate ganglion. * Evaluate the percentage of infarct size 7 days after surgery, or at discharge if the duration is shorter than 7 days. * Record their symptoms and any major adverse cardiovascular and cerebrovascular events within 30 days post-surgery.
Eligibility Criteria
Inclusion Criteria: 1. Aged ≥18 years, Male or Female. 2. Acute ST-segment elevation myocardial infarction (STEMI) patients planned for percutaneous coronary intervention (PCI). Acute STEMI is defined as: electrocardiogram shows ST-segment elevation ≥0.2 mV in two or more adjacent leads, or new left bundle branch block (LBBW). 3. Within 24 hours of the onset of infarct-related chest pain. 4. Obtaining informed consent from the patient and their family. Exclusion Criteria: 1. Patients with severe complications of myocardial infarction, such as uncontrollable acute left heart failure and pulmonary edema, severe cardiogenic shock after cardiopulmonary resuscitation, severe mechanical complications including ventricular septal defect, papillary muscle rupture, and rupture of the left ventricular free wall; 2. Patients with old myocardial infarction, or cardiomyopathy, or malignant arrhythmias controlled by antiarrhythmic drugs; 3. Patients with coagulation disorders due to systemic diseases and those who are currently using anticoagulants and are not suitable for injection; 4. Patients allergic to opioids or with a history of opioid addiction and those participating in other clinical studies; 5. Pregnant or breastfeeding women; 6. Patients with severe organ dysfunction or failure, such as liver failure, renal failure, and respiratory failure; 7. Patients with severe infections; 8. Patients with severe mental illness that cannot cooperate and those taking antipsychotic drugs; 9. Other patients considered unsuitable for this study by the researchers.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06947135 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Acute Myocardial Infarction. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06947135 currently recruiting?
Yes, NCT06947135 is actively recruiting participants. Contact the research team at xingzheruyun@126.com for enrollment information.
Where is the NCT06947135 trial being conducted?
This trial is being conducted at Hefei, China, Hefei, China, Changsha, China.
Who is sponsoring the NCT06947135 clinical trial?
NCT06947135 is sponsored by The Second Hospital of Anhui Medical University. The trial plans to enroll 166 participants.